Ultrasound findings and specific intrinsic blood volume expansion therapy for neonatal capillary leak syndrome: report from a multicenter prospective self-control study

• Published in: European journal of medical research Vol. 29; no. 1; p. 150
• Main Authors: Liu, Jing, Gao, Yue-Qiao, Fu, Wei
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 01.03.2024; BioMed Central; BMC
• Subjects: Blood pressure; Capillary leak syndrome; Care and treatment; Clinical characteristics; Comparative analysis; Disease; Edema; Health aspects; Hemoglobin; Hyperosmotic; Infants (Newborn); Infections; Intrinsic blood volume expansion; Liver; Metabolism; Mortality; NaCl; Neonate; Neonatology; Patients; Pleural effusion; Point of care testing; Potassium; Respiratory distress syndrome; Sepsis; Ultrasonic imaging; Urine; Neonate; Capillary leak syndrome; Hyperosmotic; Clinical characteristics; NaCl; Visceral edema; Point-of-care ultrasound; Intrinsic blood volume expansion
• ISSN: 2047-783X; 0949-2321; 2047-783X
• DOI: 10.1186/s40001-024-01738-2

Capillary leak syndrome (CLS) is characterized by severe systemic edema without specific treatment, resulting in a high mortality rate. This study investigated whether there is organ edema in neonatal CLS patients and specific treatment strategies to improve patient prognosis. Thirty-seven newborns diagnosed with CLS were included in this study. (1) Routine point-of-care ultrasound (POCUS) was used to identify whether the patients had visceral edema or fluid collection. (2) All patients were treated with 3% NaCl intravenously, and the clinical manifestations, laboratory indices and outcomes were compared before and after treatment. (1) Diffuse severe edema was found in 92.0% of the patients. (2) The POCUS examination revealed that CLS patients exhibited significant visceral edema in addition to diffuse severe edema, which included pulmonary edema in 67.6%, cerebral edema in 37.8%, severe intestinal edema in 24.3%, severe myocardial edema in 8.1%, pericardial effusion in 5.4%, pleural effusion in 29.7% and peritoneal effusion in 18.9%. Two patients (5.45%) had only myocardial edema without other manifestations. (3) Before and after the intravenous injection of 3% NaCl, there were no significant differences in the serum sodium or potassium levels of CLS patients, while the hemoglobin and hematocrit levels were significantly lower after treatment (p < 0.01). Her plasma ALB concentration and arterial pressure returned to normal levels after the treatment was completed. (4) All the patients survived, and no side effects or complications were observed during or after treatment with 3% NaCl. (1) In addition to diffuse severe edema, visceral edema and effusion are common and important clinical manifestations of neonatal CLS and need to be detected by routine POCUS. (2) The intravenous injection of 3% NaCl is a safe, effective and specific treatment strategy for neonatal CLS, with a survival rate of 100% and no adverse effects.